 |
Viewpoint Molecular Targeting
Heyward Coleman (CEO), Frances Johnson (CMO) and Michael Schultz (Chief Science Officer)
USA | Funding: $34.3M (+)
Website: http://viewpointmt.com/
Viewpoint Molecular Targeting develops pharmaceutical drugs for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. Our novel image-guided therapies enable a personalized approach to select patients that can benefit most and to optimize treatment planning for our targeted therapies.
Website: http://viewpointmt.com/
Viewpoint Molecular Targeting develops pharmaceutical drugs for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. Our novel image-guided therapies enable a personalized approach to select patients that can benefit most and to optimize treatment planning for our targeted therapies.
